Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vectibix in Carcinoid Syndrome
NCT01172717Phase 2Withdrawn
- Sponsor
- Boston Medical Center
- Start
- Jul 2013
- Primary completion
- Jul 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab in Carcinoid Syndrome (CS), sponsored by Boston Medical Center. Planned start Jul 2013; status: withdrawn.
02
Drugs
panitumumab
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT01172717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172717.